3-amino-4-cyclobutyl-2-oxobutanamide,hydrochloride

We are 3-amino-4-cyclobutyl-2-oxobutanamide,hydrochloride CAS:817169-86-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-amino-4-cyclobutyl-2-oxobutanamide,hydrochloride
CAS.NO:817169-86-1
Synonyms:3-amino-4-cyclobutyl-2-oxobutanamide,hydrochloride
3-AMINO-4-CYCLOBUTYL-2-OXOBUTANAMIDE HCL
 
Physical and Chemical Properties:
Molecular Formula C8H15ClN2O2
Molecular Weight 206.67000
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Boceprevir(CAS:394730-60-0).

3-amino-4-cyclobutyl-2-oxobutanamide,hydrochloride


Related News: This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.64285-95-6 At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.benzene-1,2,4-triol CAS:533-73-3 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”

Related Products
Product Name
3-Diethylaminopropylamine View Details
5-Chloro-2-fluoropyridine View Details
Sermorelin View Details
(S)-(-)-1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid manufacturer methyl-bis[[methyl(diphenyl)silyl]oxy]-phenylsilane manufacturer 2-FLUORO-3-(TRIFLUOROMETHYL)BENZOIC ACID manufacturer α-Bisabolol manufacturer 4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-2(3H)-one 4-methylbenzenesulfonate manufacturer